Cargando…
Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors
BACKGROUND: Overall survival (OS) in patients with non-small cell lung cancer (NSCLC) and brain metastases (BMs) is poor. We aimed to identify prognostic factors and ascertain treatment outcomes of first-line afatinib for patients with epidermal growth factor receptor (EGFR)-mutant NSCLC with BM in...
Autores principales: | Kim, Jehun, Jang, Tae Won, Choi, Chang Min, Kim, Mi Hyun, Lee, Sung Yong, Park, Cheol Kyu, Chang, Yoon Soo, Lee, Kye Young, Kim, Seung Joon, Yang, Sei Hoon, Ryu, Jeong Seon, Lee, Jeong Eun, Lee, Shin Yup, Park, Chan Kwon, Lee, Sang Hoon, Jang, Seung Hun, Yoon, Seong Hoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326794/ https://www.ncbi.nlm.nih.gov/pubmed/37425421 http://dx.doi.org/10.21037/tlcr-22-832 |
Ejemplares similares
-
Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea
por: Kim, Taeyun, et al.
Publicado: (2021) -
Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non–Small Cell Lung Cancer: Updated Analysis of the RESET Study
por: Kim, Taeyun, et al.
Publicado: (2023) -
Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
por: Lee, Sung Yong, et al.
Publicado: (2021) -
Clinical impact of rebiopsy among patients with epidermal growth factor receptor‐mutant lung adenocarcinoma in a real‐world clinical setting
por: Nam, Yunha, et al.
Publicado: (2021) -
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
por: Lee, Jang Ho, et al.
Publicado: (2023)